2024年11月19日 · In this study, we aimed to evaluate the prevalence and heterogeneity of mRNA and immunohistochemistry (IHC) expression of DLL3 at different subcellular compartments in …

2019年3月20日 · The objective of this study was to evaluate the expression of DLL3 across various stages of prostate cancer using different platforms (IHC, NanoString, and RNA-seq) …

Delta-like ligand 3 (DLL3) is an inhibitory ligand of the Notch signaling pathway that downregulates Notch signaling during neuroendocrine differen-tiation. DLL3 is...

2023年5月31日 · DLL3 testing methods varied across studies, with immunohistochemistry (IHC) being used in 26 (86.7%) studies. Two studies used real-time polymerase chain reaction, one …

2019年6月18日 · Here, we review the preclinical and clinical evidence for targeting DLL3 in SCLC and discuss several DLL3-specific therapies being developed for the treatment of SCLC: the …

2023年9月20日 · Approximately 85% of SCLC cases are positive for DLL3 in immunohistochemistry (IHC) [4, 5, 6]. In addition, DLL3 is regulated by ASCL1, a transcription …

Background: Delta-like protein 3 (DLL3) is a transmembrane protein that is implicated in the tumorigenesis of small cell lung cancer (SCLC). The ability to quantify DLL3 protein may be …

2024年10月1日 · This study aimed to assess DLL3 expression in early-stage SCLC tumors using immunohistochemistry (IHC) and mRNA in situ hybridization (ISH), correlate these assays with …

This study aimed to assess DLL3 expression in early-stage SCLC tumors using immunohistochemistry (IHC) and mRNA in situ hybridization (ISH), correlate these assays with …

近期，在国际学术期刊《Clinical Cancer Research》在线发表题为“AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in …